Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study

Stephan Michels, Philip J. Rosenfeld, Carmen A. Puliafito, Erin N. Marcus, Anna S. Venkatraman

Research output: Contribution to journalArticlepeer-review

590 Scopus citations

Fingerprint

Dive into the research topics of 'Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study'. Together they form a unique fingerprint.

Medicine & Life Sciences